Literature DB >> 12767600

Opposite vascular activity of (R)-apomorphine and its oxidised derivatives. Endothelium-dependent vasoconstriction induced by the auto-oxidation metabolite.

Belén Abarca1, Rafael Ballesteros, Patricia Bielsa, Juan Moragues, Pilar D'Ocon, Eugenia García-Zaragozá, M Antonia Noguera.   

Abstract

We have synthetised a series of oxidised apomorphine derivatives (orto and para quinones 2-5), in order to analyse their vascular activity. We have performed radioligand binding assays on rat cortical membranes and functional studies on rat aortic rings. Instead the relaxant activity exhibited by (R)-apomorphine, o-quinones 2, 4, show contractile activity dependent on endothelium in rat aortic rings. Compound 2, the main metabolite of (R)-apomorphine auto-oxidation, was the product which showed enhanced contractile activity by a complex mechanism related to activation of Ca(2+) channels through release and/or inhibition of endothelial factors. Moreover, this compound disrupts the endothelial function as shows the lack of response to acetylcholine observed in vessels pretreated with it.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767600     DOI: 10.1016/s0223-5234(03)00057-6

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  Sphingosine 1-phosphate-mediated α1B-adrenoceptor desensitization and phosphorylation. Direct and paracrine/autocrine actions.

Authors:  Jean A Castillo-Badillo; Tzindilú Molina-Muñoz; M Teresa Romero-Ávila; Aleida Vázquez-Macías; Richard Rivera; Jerold Chun; J Adolfo García-Sáinz
Journal:  Biochim Biophys Acta       Date:  2011-10-13

2.  Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum.

Authors:  Kenshi Matsumoto; Masaki Yoshida; Karl-Erik Andersson; Petter Hedlund
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

3.  Stability of apomorphine in solutions containing selected antioxidant agents.

Authors:  Zen Yang Ang; Michael Boddy; Yandi Liu; Bruce Sunderland
Journal:  Drug Des Devel Ther       Date:  2016-10-03       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.